Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203408 | 0.82 | FABP4 (0.60) | MAPTALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL2677242 | 0.82 | FABP4 (0.60) | MAPTALDH1A1SMN1; SMN2L3MBTL3KMT2A | |
| SCHEMBL20314704 | 0.81 | L3MBTL3 (0.74) | MAPTALDH1A1SMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL6527758 | 0.80 | HSD17B10 (0.57) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL29306677 | 0.80 | L3MBTL3 (0.66) | MAPTALDH1A1SMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL13079743 | 0.80 | SMN1; SMN2 (0.70) | MAPTALDH1A1SMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL2945763 | 0.79 | ALDH1A1 (0.69) | MAPTALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL2941926 | 0.78 | MAPK1 (0.65) | ALDH1A1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL5960050 | 0.77 | ALDH1A1 (0.77) | MAPTALDH1A1SMN1; SMN2L3MBTL3KMT2A | |
| SCHEMBL5960104 | 0.77 | ALDH1A1 (1.00) | MAPTALDH1A1SMN1; SMN2L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750005-B2 | Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-1599480-B1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080221113-A1 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7390814-B2 | Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| CN-100363364-C | Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments | AVENTIS PHARMA GMBH (DE) | 2008-01-23 | — | — | CN | disclosed |
| CN-1751046-A | Substituted hexahydropyrazino (1, 2-a) pyrimidine-4, 7-dione derivatives, method for the production thereof and use thereof as medicaments | AVENTIS PHARMA GMBH (DE) | 2006-03-22 | — | — | CN | disclosed |
| EP-1599480-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004072076-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221113-A1 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DPYD, TYMP, DHPS | MAPT 4489/4885ALDH1A1 136/4885SMN1; SMN2 1998/4885 |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, TYMP, G6PD | MAPT 4429/4885ALDH1A1 129/4885SMN1; SMN2 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.